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Abstract
Objectives: In Lagos, Nigeria, Me´decins Sans Frontie`res (MSF) and the Ministry of Health (MoH) commenced free
antiretroviral treatment (ART) in a hospital-based clinic. We performed a cross-sectional study to compare factors associated
with raised viral load between patients with (‘‘experienced’’) and without (‘‘naı¨ve’’) prior antiretroviral (ARV) exposure at
commencement of ART at the clinic. We also examined factors influencing ARV adherence in experienced patients prior to
clinic entry.
Methods: We included adult patients receiving ART from MSF who answered a questionnaire about previous antiretroviral
use. Multivariate logistic regression was used to estimate odds ratios (OR) for raised viral load ($1000 copies/mL).
Results: 1246 (96%) patients answered: 1075 (86%) reported no, and 171 (14%) some, prior ARV exposure. ARV-naı¨ve
patients were more immunosuppressed at baseline: 65% vs 37% (p,0.001) had CD4,200; 17% vs 9% (p = 0.013) were WHO
stage 4. Proportionately more experienced than naı¨ve patients had raised viral loads (20% vs 9%, p,0.001) on ART in the
MSF/MoH clinic. Raised viral load was associated with prior ARV experience (adjusted OR = 3.74, 95%CI 2.09–6.70, p,0.001)
and complete interruption of current ART (adjusted OR = 3.71, 95%CI 2.06–6.68, p,0.001). Higher CD4 at time of VL and a
higher self-rated score of recent adherence were associated with lower OR of a raised viral load. Among experienced
patients who missed pills before joining MSF/MoH, most common reasons were because ARVS were not affordable (58%) or
available (33%), with raised viral load associated with being unsure how to take them (OR = 3.16, 95%CI 1.10–9.12, p = 0.033).
Conclusions: Patients previously exposed to ARVs had increased OR of raised viral load. The cost and availability of ARVs
were common reasons for missing ARVs before joining the MSF/MoH clinic, and inadequate patient knowledge was
associated with raised viral load.
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Introduction
Access to non-nucleoside reverse transcriptase inhibitor
(NNRTI) based antiretroviral therapy (ART) in resource-limited
settings has lowered HIV-related morbidity and mortality [1].
However, the NNRTIs available in these settings have a low
genetic barrier to resistance and high degree of cross-resistance
[2]. Patients who develop immunological or virological failure and
remain on first line ART have a 2.5 fold increased risk of death
compared to those switched to second line ART [3]. In sub-
Saharan Africa, treatment interruptions are common [4] and are
associated with ART resistance [5] and treatment failure [6,7].
Although rates of adherence in Africa have been reported as high
[8,9,10], financial constraints are linked with poor adherence,
while provision of free ART is associated with improved survival
[11,12].
Data are limited on the outcomes of antiretroviral (ARV)
experienced patients commenced on NNRTI-based ART in
resource-limited settings. A recent study from Africa showed a
two-fold increased risk of virological failure in those previously
exposed to ART [13]. In Cambodia, previous sub-optimal ART
was associated with lower virological success [14]. Prior exposure
to single-dose nevirapine in prevention of mother-to-child
transmission (PMTCT) programmes has been associated with an
increased risk of virological failure [15]. In South Africa, 19% of a
cohort on first-line ART had virological failure, predicted by prior
exposure to ARVs or less than 95% adherence to drug refills [16].
In Kenya, ARV-experienced patients were healthier at baseline,
and had lower mortality compared with naı¨ve patients [17]. A
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meta-ethnography in sub-Saharan Africa reported key barriers to
adherence that included quality of services, treatment-related
costs, social support networks, and service delivery that focuses on
the individual [18]. A cross-sectional relationship between
adherence and virological suppression has been demonstrated
[19] and baseline adherence is predictive of long-term virological
failure [20]. However factors associated with treatment interrup-
tions in ART-experienced patients and their direct association
with virological failure on NNRTI-based first-line treatment in
Africa have not been determined.
In 2003 in Lagos, Nigeria, free, accessible ART was scarce,
resulting in many patients self-funding ART in the private sector,
or co-paying in government subsidised care. In this setting of
limited availability of ARVs with stock-outs, self-funded treatment,
and ARVs sometimes obtained through non-medical sources, it
was not uncommon for patients to take inadequate treatment.
Me´decins Sans Frontie`res (MSF) and the Lagos State Ministry of
Health (MoH) commenced provision of ART in an urban
hospital-based clinic in 2003. ART, drugs for opportunistic
infections (OIs), and diagnostic tests were provided free of charge,
and there were no interruptions to ARV drug supplies. In the
absence of genetic resistance testing, and with the greater costs of
second-line treatment, most patients were commenced on WHO-
recommended first-line ART with an NNRTI-based ART
regimen irrespective of prior ARV exposure and whether those
with prior exposure had unplanned or unstructured treatment
interruptions [21].
In this cross-sectional study we assessed the OR of raised viral
load comparing patients with (‘‘experienced’’) and without
(‘‘naı¨ve’’) prior ARV exposure at commencement of ART at the
MSF/MoH HIV clinic in Lagos, Nigeria. We also examined
factors influencing ART adherence in experienced patients prior
to entry into the clinic and examined their association with raised
viral load.
Methods
We analysed data from adult patients receiving ART from MSF
who consented to use of their HIV-related medical data for non-
clinical purposes and who answered all relevant questions in a
standardised pilot-tested questionnaire about ARV use before
enrolling for treatment (Figure 1). The questionnaire was
administered once to all adult patients currently taking ART in
the MSF/MoH programme between October 2007 and April
2008 by trained adherence counsellors. It was performed as part of
routine patient management to assess ARV use prior to MSF
treatment and current adherence in order to facilitate better
clinical management. It used a chart with ARV names and images
to aid recall, and asked if any ARVs had ever been taken before
they started coming to the free MSF clinic. If any ARVs (including
PMTCT) had previously been taken, the timing, combinations,
period of consumption, treatment interruptions and adherence
challenges were explored by further questioning the patient.
Complete interruption was defined as not having taken the
mentioned ARV at all for 1 or more weeks in a row; partial
interruption was defined as not having taken the full amount of the
mentioned ARV for 1 or more weeks in a row. Current adherence
was assessed at the time the questionnaire was administered with a
visual 10-point scale to self-score medical adherence (1 = took no
medication; 10= took every dose in the last month) and timing of
last completely missed dose as reported by the patient.
Patients were categorised into two groups according to their
prior ARV exposure at commencement of ART at the MSF/
MoH HIV clinic: experienced (with prior exposure) or naı¨ve
(without prior exposure). Because experience ranged widely from
less than 1 month to 72 months, experienced patients were further
categorised by duration of reported prior exposure: ,6 months,
$6 months, or unknown. We used ‘‘MSF/MoH-ART’’ to specify
the time on treatment at our clinic, as distinct from ARVs taken
prior to joining our clinic. We used the term ARV rather than
ART to denote prior experience because during prior treatment
patients did not all take triple ARV combination therapy.
Routine clinical data were collected by clinical staff at each
clinical consultation and entered into a standardised electronic
database (FUCHIA, Epicentre, Paris). HIV viral load (VL) testing
was performed to facilitate programme review over the year
encompassing the questionnaire period as was feasible, but was not
available routinely due to programmatic restrictions. The first
HIV viral load (VL) measurement for each patient after at least 6
months of MSF/MoH-ART was included. VL was measured at
an independent laboratory using Bayer Versant HIV-1 RNA 3.0
bDNA assay with Bayer System 340 bDNA Analyzer (Bayer
Diagnostics, Tarrytown, NY, USA) using samples prepared
according to Versant guidelines and with quality control
monitored by MSF. CD4 count was routinely measured at 6
monthly intervals by FACScount, with the result at start of ART
and within 90 days of the time of the VL included in this analysis.
Data were analysed using STATA 10.1 (StataCorp, Texas,
USA). Baseline characteristics were described using medians and
interquartile range (IQR) for continuous variables, and counts and
percentages for categorical variables. Characteristics were com-
pared between ARV history using Kruskal-Wallis rank sum test for
medians of continuous variables, and odds ratios (ORs) with 95%
confidence intervals (CIs) for binomial variables. All p values are
exact and two-tailed; p,0.05 was considered significant.
Multivariate regression was used to estimate ORs for raised viral
load (VL$1000 copies/mL) at any time $6 months of MSF/
MoH-ART for ARV-experienced versus naı¨ve patients, adjusting
for potential confounders of biological or programmatic impor-
tance: sex; baseline age, body mass index and WHO stage (4 or 1–
3); CD4 count (,200, 2002,350,$350 cells/mL) at baseline and
closest measurement to (and within 90 days of) the VL
measurement; months on MSF/MoH-ART when VL was
measured; whether MSF/MoH-ART had ever been completely
interrupted or partially interrupted; and self-assessment of current
adherence. A second more limited multivariate regression model
examined only experienced patients and some additional factors
related only to previous ARV history before starting MSF/MoH-
ART, retaining only key characteristics and variables with p#0.10
on unadjusted analysis. Only patients with all data available were
included, but a sensitivity analysis was done to include patients
with missing WHO and CD4 stage as the key contributors to
missing data.
Ethics statement
Patients gave written informed consent for use of their clinical
data, and in addition gave verbal informed consent before
answering the questionnaire, documented by the interviewer.
The study including questionnaire and consent documents were
approved by the MSF Ethics Review Board. Coded identification
numbers were used to match questionnaire data with routine
clinical data, and personal identifiers removed.
Results
Comparison of patients by prior ARV experience
1246 (96%) of 1297 adult patients on ART during Oct 2007-
April 2008 answered the questionnaire: 1075 (86%) reported no
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and 171 (14%) some prior ARV exposure (Figure 1). Of these,
1165 (93% of naı¨ve and 95% of experienced) patients had a VL
test after $6 months of current ART and 1027 (83% of naı¨ve and
78% of experienced) had complete data allowing their inclusion in
the regression model. Patients excluded due to missing data
(n = 219) were not different (where data were available) from
Figure 1. Patient inclusion.
doi:10.1371/journal.pone.0071407.g001
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included patients in gender, age or body-mass index at baseline,
however a greater proportion of patients missing some data were
WHO stage 4 at baseline (19% vs. 15%; p,0.001) and had
CD4$350 cells/mL at baseline (11% vs. 7%; p,0.001) (data not
shown). A similar proportion of experienced and naı¨ve patients
were missing baseline CD4 counts (4% vs. 5%, p= 0.39), but more
experienced than naı¨ve patients were missing WHO stage (11% vs.
3%, p,0.001). Amongst 631 adult patients who had started ART
at last visit but were not included as they had died, transferred or
were lost to follow-up by the time of the questionnaire (Figure 1),
baseline characteristics were similar to those included in terms of
gender (65% female), age (median 35.0; IQR 29.4–41.1), body-
mass index (median 20.6; IQR 18.5–23.4), and baseline CD4
(median 147 cells/mL; IQR 59–255), but a slightly greater
proportion were in WHO stage 4 (21%). For the included cohort,
the median time between answering the questionnaire and VL
measurement was 0 months (IQR 22.1 to 2.3). At baseline,
experienced patients had better clinical and immunological status
than naı¨ve patients (Table 1), but age and sex did not differ.
Although initial CD4 count when commencing ART with
MSF/MoH was higher in experienced patients (271 vs 140 cells/
mL, p,0.001), increase in CD4 after 12 months of MSF/MoH-
ART was higher for naı¨ve patients (median gain 180 vs 90 cells/
mL, p,0.001). Nonetheless, at the time VL was measured, CD4
remained higher in experienced patients (436 vs 370 cells/mL,
p= 0.013). After $6 months of ART, proportionately more
experienced patients had raised viral load (20% vs 9%, p,0.001),
although they were assessed after a slightly longer time on MSF/
MoH-ART (26.7 vs 22.1 months, p,0.001) (Table 1). A higher
proportion of experienced patients were switched to second-line
ART (5% vs 1%, p,0.001), but numbers were small in both
groups (Table 1). Proportionately, more naı¨ve patients had
completely interrupted their MSF/MoH-ART (10% vs 5%,
p= 0.036), but partial interruptions of MSF/MoH-ART or
recently missed doses did not differ between groups (Table 1).
Raised viral load after $6 months of MSF/MoH-ART was
associated with prior ARV experience (adjusted OR=3.74,
p,0.001) and complete interruption of MSF/MoH-ART (3.71,
p,0.001). Higher CD4 when VL was measured was associated
with a lower OR for raised viral load (adjusted OR=0.30 for CD4
2002,350 cells/mL, and 0.16 for CD4$350 cells/mL compared
with CD4,200 cells/mL, both p,0.001), as was a higher self-
rated score of recent adherence (adjusted OR=0.74 for each
additional point on the scale, p,0.001) (Table 2). Increasing the
threshold for raised viral load to 5000 copies/mL did not
substantially change the direction or magnitude of adjusted OR
in the model, but partial interruption of MSF/MoH-ART was no
longer significantly associated with raised viral load (results not
shown). The model was also robust to including patients with
missing WHO stage and CD4 count (data categorised as ‘missing’
rather than excluded; model n= 1119, 90% of patients who
answered questionnaire). The variable partial interruption of
MSF/MoH-ART became more strongly associated (p= 0.026)
with raised viral load, indicating that the association of this
variable with failure is somewhat sensitive to model conditions and
thus not as important a factor as others shown to be very strongly
Table 1. Baseline characteristics, immunological and virological markers and current ART adherence.
ARV naı¨ve (n = 1075) ARV experienced (n = 171) p
Baseline
Female n (%) 670 (62%) 107 (63%) 0.95
Age (years); median (IQR) 35.7 (30.1, 42.2) 36.1 (31.0, 42.0) 0.57
Body mass index (kg/m2); median (IQR) 21.0 (18.9, 23.6) 22.7 (20.3, 26.0) ,0.001
Haemoglobin (g/dL); median (IQR) 10.1 (8.8, 11.2) 11.4 (10.0, 12.2) ,0.001
CD4 (cells/mL); median (IQR) (n = 1186) 140 (61, 227) 271 (147, 431) ,0.001
CD4,200 cells/mL; n (%) 693 (65%) 63 (37%) ,0.001
WHO stage 4; n (%) 179 (17%) 14 (9%) 0.013
Immunological and virological markers
CD4 change (cells/mL) at 12 months MSF/MoH-ART;
median (IQR) [n; %]
180 (105, 276) [970; 90%] 90 (20, 178) [159; 93%] ,0.001
CD4 (cells/mL) at time of VL; median (IQR) [n; %] 370 (252, 544) [986; 92%] 436 (285, 613) [158; 92%] 0.013
VL (copies/mL) at $6 months MSF/MoH-ART; median (IQR) [n; %] 50 (50, 71) [1003; 93%] 50 (50, 344) [162; 95%] ,0.001
VL #1000 copies/mL at $6 months MSF/MoH-ART; n (%) 912 (91%) 130 (80%) ,0.001
Time (months) on MSF/MoH-ART at time of VL; median (IQR) [n; %] 22.1 (14.3, 27.8) [1003; 93%] 26.7 (19.6, 29.1) [162; 95%] ,0.001
Time (months) on MSF/MoH-ART at time of questionnaire;
median (IQR) [n; %]
21.4 (14.7, 27.9) [1075; 100%] 26.8 (19.1, 30.5) [171; 100%] ,0.001
Switched from NNRTI to PI within 18 months MSF/MoH-ART; n (%) 9 (1%) 9 (5%) ,0.001
Current (with MSF/MoH) adherence to ART
Completely interrupted MSF/MoH-ART $1 time(s); n (%) 103 (10%) 8 (5%) 0.036
Partially interrupted MSF/MoH-ART $1 time(s); n (%) 32 (3%) 4 (2%) 0.64
Last missed dose within last 2 weeks; n (%) 64 (6%) 11 (6%) 0.81
Self-score on adherence (scale 0–10) $8; n (%) 957 (89%) 160 (94%) 0.07
ART = antiretroviral therapy. ARV = antiretroviral. IQR = interquartile range. VL = viral load. NNRTI = non-nucleoside reverse transcriptase inhibitor. PI = protease inhibitor.
MSF/MoH = Me´decins Sans Frontie`res/Ministry of Health.
doi:10.1371/journal.pone.0071407.t001
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associated with raised viral load and whose associations did not
change significantly in this sensitivity analysis.
Characteristics of patients with prior ARV experience
Women were more likely to have had longer prior ARV
exposure (68% of patients with $6 months prior ARV exposure
were women vs 46% with ,6 months [p = 0.012]). Three women
had PMTCT as their only previous ARV exposure, and a further
21 also had used ARVs at other times. Patients with $6 months of
prior exposure compared with those with ,6 months had higher
body mass index (23.9 vs 21.2 kg/m2, p,0.001), haemoglobin
(11.6 vs 10.8 g/dL, p = 0.027) and CD4 at baseline (305 vs 212
cells/mL, p= 0.011), but a similar proportion were in WHO
clinical stage 4 (8% vs 10%, p= 0.85). After $6 months of MSF/
MoH-ART the prior exposure groups did not differ in immuno-
logical or virological status (data not shown). Those with $6
months prior experience were more likely to have taken $1
NNRTI(s), and a combination of $3 ARVs (Table 3). There was
little difference in reported previous ARV adherence (Table 3) or
recent MSF/MoH-ART adherence (data not shown) between
prior exposure groups, except that a greater proportion of those
who had taken ARVs for$6 months reported having missed some
pills.
Of 164 experienced patients who were asked via the question-
naire whether they ever missed any pills during the time they took
ARVs before joining MSF, 99 (60%) reported they had missed
pills sometimes, including 32 patients who missed pills but not
enough to meet our definition of complete or partial ARV
interruption. The most common reasons for experienced patients
missing pills before joining our clinic were that they could not
afford to buy ARVs (58%), could not get them due to a stock
rupture (33%), or forgot (31%) (Table 4). Raised viral load in
experienced patients was associated with reporting having missing
pills before joining MSF because they ‘‘were not sure when and
how to take them’’ (OR 3.16, p = 0.033) (Table 4). The association
with raised viral load was weaker in those who reported that they
had missed pills before joining MSF because they were unable to
afford ARVs (OR 1.76, p = 0.16), although this may have been
strengthened if the study had larger numbers.
Multivariate analysis for raised viral load among only patients
with prior experience and sufficient data (n = 154) indicated that
CD4 at the time of VL measurement was associated with raised
viral load in a similar way to the entire cohort: a higher CD4 at the
time of VL was associated with lower OR for raised viral load.
Additionally, complete interruption of MSF/MoH-ART remained
associated with a high OR for raised viral load (adjusted
OR=13.52, p = 0.009), and although the point estimate of the
association of recent adherence self-score was nearly the same as
for the entire cohort (OR=0.76), it was less strongly associated
(p = 0.19) (Table 5). CD4 at ART initiation interacted with CD4 at
the time of VL becoming no longer associated with raised viral
load without modifying other variable associations, so was
excluded. Partial ARV interruption prior to joining MSF was
associated with a raised viral load (adjusted OR=3.94, p = 0.024),
Table 2. Logistic regression model for raised viral load any time after $6 months on MSF/MoH-ART (n = 1027).
OR (95% CI) p Adjusted OR (95% CI) p
Previous ARV experience
Naı¨ve 1 1
Experienced 2.47 (1.58–3.84) ,0.001 3.74 (2.09–6.70) ,0.001
Sex
Female 1 1
Male 1.14 (0.77–1.68) 0.52 1.29 (0.80–2.09) 0.29
Age at MSF/MoH-ART initiation 0.98 (0.96–1.01) 0.14 0.98 (0.95–1.01) 0.13
Body mass index at MSF/MoH-ART initiation 1.00 (0.96–1.04) 0.98 1.00 (0.95–1.06) 0.98
WHO stage at MSF/MoH-ART initiation
1–3 1 1
4 0.97 (0.57–1.64) 0.90 0.77 (0.41–1.46) 0.43
CD4 at MSF/MoH-ART initiation
,200 1 1
2002,350 0.74 (0.47–1.17) 0.20 1.04 (0.57–1.89) 0.89
$350 0.83 (0.40–1.71) 0.61 0.83 (0.31–2.26) 0.72
CD4 at time of VL
,200 1 1
2002,350 0.35 (0.22–0.57) ,0.001 0.30 (0.17–0.52) ,0.001
$350 0.20 (0.13–0.32) ,0.001 0.16 (0.08–0.30) ,0.001
While taking MSF/MoH-ART:
Self-score of adherence to MSF/MoH-ART 0.72 (0.62–0.83) ,0.001 0.74 (0.63–0.87) ,0.001
Ever completely interrupted MSF/MoH-ART 4.34 (2.69–6.99) ,0.001 3.71 (2.06–6.68) ,0.001
Ever partially interrupted MSF/MoH-ART 4.34 (2.00–9.46) ,0.001 2.34 (0.88,6.18) 0.087
Time on MSF/MoH-ART at time of VL 0.98 (0.96–1.01) 0.16 0.98 (0.96–1.01) 0.27
ART = antiretroviral therapy. OR = odds ratio. CI = confidence interval. ARV = antiretroviral. VL = viral load. MSF/MoH = Me´decins Sans Frontie`res/Ministry of Health.
doi:10.1371/journal.pone.0071407.t002
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but ever missing pills was not strongly associated (Table 5).
Increasing the threshold for raised viral load to 5000 copies/mL
did not substantially change the direction or magnitude of adjusted
OR in the model, but partial interruption prior to joining MSF
was no longer significantly associated, whereas self-score on recent
adherence became significantly associated with raised viral load
(results not shown).
Discussion
Our study comparing raised viral load between ARV naı¨ve and
experienced patients in a resource-limited setting showed that
patients with any previous exposure to ARVs had a nearly 4-fold
greater OR of raised viral load in the MSF/MoH-ART
programme, despite reporting better adherence to current ART
regimens and being healthier when starting MSF/MoH-ART. It is
possible that baseline resistance to first-line ARVs contributed to
this finding, although we did not do baseline genotypic resistance
testing to enable us to confirm this suspicion. In our cohort, many
of the ARV-experienced patients had interrupted their ARVs
prior to treatment in the MSF/MoH programme and treatment
interruptions are associated with the development of ARV
resistance [5,22,23,24]. Recent findings support ours, showing
that if resistance to any first-line ARVs is present at baseline,
Table 3. History of ARV use (before MSF/MoH-ART) in ARV-experienced patients.
Total
(n = 168)*
,6 months on
ARVs (n = 54)
$6 months on
ARVs (n = 96)
Unknown time on
ARVs (n = 18) P
Previous ARVs included $1 NNRTIs; n (%) 105 (62%) 29 (54%) 69** (72%) 7 (39%) 0.009
Previous ARVs included a PI; n (%) 2 (1%) 1 (2%) 1 (1%) 0 1.00
Took combination of 3 or more ARVs; n (%) 70 (42%) 19 (35%) 49 (51%) 2 (11%) 0.005
Took ARVs as dual therapy only{; n (%) 11 (6%) 6 (11%) 4 (4%) 1 (6%)
Completely interrupted $1 ARV(s); n (%) 65 (39%) 19 (35%) 40 (42%) 6 (33%) 0.69
Partially interrupted $1 ARV(s); n (%)` 39 (23%) 10 (19%) 26 (27%) 3 (17%) 0.44
Missed any ARVs; n(%) 99 (60%)`` 25 (48%) 65 (69%) 9 (50%) 0.029
*3 PMTCT (prevention of mother-to-child transmission) patients excluded as questionnaire incomplete.
**4 patients reported prior use of 2 NNRTIs;
{includes 7 patients who took an ‘‘unknown’’ combination and 3 who took 2 pills one of which was a single ARV and the other unknown.
`29 patients reported both complete and partial interruption at different times.
``4 patients could not remember.
ARV = antiretroviral. NNRTI = non-nucleoside reverse transcriptase inhibitor. PI = protease inhibitor. MSF/MoH = Me´decins Sans Frontie`res/Ministry of Health. Completely
interrupted = did not take mentioned ARV at all $1 week(s) in a row. Partially interrupted = did not take mentioned ARV in full amount $1 week(s) in a row.
doi:10.1371/journal.pone.0071407.t003
Table 4. Reasons for missing ARVs before joining the MSF/MoH clinic and association with raised viral load in ARV-experienced
patients after $6 months on MSF/MoH-ART (n = 158).
Reason for missing pills
n (% of those who missed
pills) OR (95% CI) p
Ever missed any pills 99 (100%) 1.66 (0.76–3.60) 0.20
forgot 31 (31%) 0.99 (0.37–2.70) 0.99
shared your pills with someone else 5 (5%) –
could not afford to buy them all 57 (58%) 1.76 (0.80–3.88) 0.16
could not get them (stock out) 33 (33%) 1.31 (0.53–3.26) 0.57
wanted to avoid side-effects 6 (6%) 1.98 (0.35–11.34) 0.44
felt ill 5 (5%) –
felt well and wanted to stop 9 (9%) 1.30 (0.25–6.77) 0.76
did not have food to eat when taking pills 5 (5%) –
not sure when and how to take them 18 (18%) 3.16 (1.10–9.12) 0.033
overslept 17 (17%) 1.21 (0.37–3.99) 0.76
had another sickness like malaria 3 (3%) – –
did not want others to know 4 (4%) –
had too many pills to take 2 (2%) – –
were away from home 17 (17%) 1.87 (0.60–5.83) 0.28
pills were lost or stolen 2 (2%) –
some other reason 7 (7%) 1.98 (0.35–11.34) 0.44
ART = antiretroviral therapy. OR = odds ratio. VL = viral load. CI = confidence interval. MSF/MoH = Me´decins Sans Frontie`res/Ministry of Health.
doi:10.1371/journal.pone.0071407.t004
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patients are at a two-fold increased risk of developing virological
treatment failure on first-line NNRTI-based ART in Africa [13].
Of note, the World Health Organisation recommend using the
threshold of 5000 copies/mL to determine virological failure [25].
However we used the threshold of 1000 copies/mL as episodes of
this level are associated with ARV resistance and clinical events
[26], and factors associated with raised viral load in our study were
similar when the threshold was raised to 5000 copies/mL on
sensitivity analysis.
Although the effect of prior ART exposure on virological
outcomes for first-line ART in Africa [13] and reasons for poor
adherence to ART [12,27,28] have been examined, we uniquely
describe the factors associated with previously missing ARVs in
ART-experienced patients and examine their association with
raised viral load on current first-line treatment. The most common
reasons for missing pills prior to the MSF/MoH-ART programme
were not being able to afford ARVs, lack of availability due to
stock rupture, or forgetting, while the reason most strongly
associated with raised viral load was lack of knowledge. Most of
these can be addressed, some with fewer resources than others,
such as by improving patient treatment education and under-
standing. Free provision of HIV care is also vitally important as it
has been associated with lower rates of virological failure and
mortality [12,29], and with a 29–31% higher probability of
virological suppression [30]. Yet despite the benefits of abolishing
user fees, such as greater access to services [31], in many settings
they remain in place as evidenced by a meta-analysis of ART
programmes in resource-limited settings showing six of ten
programmes charged user fees [30].
Most experienced patients in our cohort were not found to have
raised viral load. Nevertheless, the higher rate of raised viral load
in these patients supports the need to develop adapted ART
Table 5. Logistic regression model for raised viral load after $6 months on MSF/MoH-ART in ARV-experienced patients (n = 154).
OR
(95% CI) p
Adjusted OR
(95% CI) p
Sex
Female 1 1
Male 0.80 (0.36–1.77) 0.58 0.97 (0.32–2.99) 0.96
Age at ART initiation 1.05 (0.99–1.11) 0.090 1.00 (0.94–1.08) 0.92
Body mass index at ART initiation 1.01 (0.94–1.08) 0.83 Not included
WHO stage at ART initiation
1–3 1 Not included
4 0.64 (0.13–3.03) 0.57
CD4 at ART initiation
,200 1 Not included
2002,350 0.37 (0.14–0.98) 0.045
$350 0.29 (0.10–0.79) 0.016
CD4 at time of VL
,200 1 1
2002,350 0.26 (0.08–0.82) 0.022 0.26 (0.07–0.99) 0.049
$350 0.08 (0.03–0.21) ,0.001 0.08 (0.02–0.26) ,0.001
While taking ART with MSF:
Self-score of adherence to MSF/MoH-ART 0.68 (0.51–0.91) 0.009 0.76 (0.50–1.15) 0.19
Ever completely interrupted MSF/MoH-ART 6.05 (1.28–28.68) 0.023 13.52 (1.92–95.40) 0.009
Ever only partially interrupted MSF/MoH-ART 4.27 (0.57–31.72) 0.16 Not included
Time on MSF/MoH-ART at time of VL 0.94 (0.89–0.99) 0.028 0.93 (0.87–0.99) 0.036
Previous ARV history
,6 months in total on ARVs 1 Not included
$6 months on ARVs 1.25 (0.52–2.99) 0.62
Unknown time on ARVs 1.05 (0.25–4.47) 0.95
Previous ARVs included $1 NNRTI(s) 1.70 0.73–3.98) 0.22 Not included
No ARV combinations 1 Not included
Only 2 ARVs in combination 0.55 (0.06–4.77) 0.59
3 ARVs in combination 1.67 (0.75–3.70) 0.21
Ever completely interrupted ARVs 1.89 (0.86–4.14) 0.11 Not included
Ever only partially interrupted ARVs 3.82 (1.65–8.83) 0.002 3.94 (1.20–12.92) 0.024
Ever missed any pills 1.66 (0.80–3.42) 0.17 1.32 (0.45–3.91) 0.61
VL = viral load. ART = antiretroviral therapy. ARV = antiretroviral. OR = odds ratio. NNRTI = non-nucleoside reverse transcriptase inhibitor. MSF/MoH = Me´decins Sans
Frontie`res/Ministry of Health. WHO = World Health Organisation. Number of patients with raised viral load included in model = 32 (21%).
doi:10.1371/journal.pone.0071407.t005
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initiation algorithms for those previously exposed to ART,
particularly as NNRTI-based regimens are used which have a
low genetic barrier to resistance [2]. This would include the
availability of simple, reliable and affordable viral resistance
genotyping procedures for use at ART baseline [32] and
alternative first-line regimens for those with demonstrated first-
line ARV resistance.
Experienced and naı¨ve patients did not differ significantly in
non-health demographics, but when starting ART with MSF,
experienced patients had higher body mass index, haemoglobin,
CD4 counts and a lower proportion in WHO clinical stage 4,
probably as a result of the beneficial effect of prior ARVs. This
occurred despite 60% of experienced patients reporting missing
some pills before joining the MSF/MoH clinic, and 23% reporting
partial treatment interruption and 39% complete treatment
interruption before commencing with MSF (Table 3).
Factors associated with raised viral load after $6 months of
MSF/MoH-ART were previous ARV experience, low CD4 at the
time of VL, lower self-reported adherence, and interruptions to
ART while treated by MSF (Table 2). Self-reported adherence
rates were high and appeared effective in predicting actual
adherence as increasing rates correlated with decreased OR of
raised viral load. Adherence to MSF/MoH-ART was not different
between previously experienced and naı¨ve patients (Table 1), but
MSF/MoH-ART adherence score was associated with raised viral
load in the whole cohort (Table 2) and also the experienced cohort
only (Table 5). This provides support to findings from previous
studies where self-reported adherence rates were strongly associ-
ated with virological failure [13,33,34]. ART treatment interrup-
tions are known to increase the risk of opportunistic infections and
death in an African context [35] and have also been associated
with virological treatment failure in South Africa [1,36]. Efforts to
minimise treatment interruptions are important in maximising the
beneficial effects of ART, and therefore understanding the reasons
for treatment interruptions is vital in addressing this important
issue.
The primary limitation of this study is the cross-sectional design,
resulting in a potential survival bias as patients who died or were
lost to follow-up before the questionnaire was administered were
not included, however in most baseline factors those not included
and included were similar. A secondary limitation is the possibility
of recall bias in reporting prior exposure to ARVs. This risk was
minimised by using picture charts of all potentially available
ARVs, and cross-checking questionnaire results with patient
admission notes. Additionally we did not determine reasons for
missing pills while at the MSF/MoH clinic, and therefore we were
unable to compare recent challenges with those reported by ARV
experienced patients who missed pills prior to programme entry,
nor assess any association with raised viral loads in our study,
however common reasons in experienced patients such as cost and
availability were no longer relevant as the MSF/MoH clinic
provided free reliable care. A third limitation is that while the
patients who did not have complete data for inclusion in the
regression model were demographically similar, they differed to
those included on some clinical characteristics, notably baseline
WHO stage and CD4 counts, and for WHO stage proportion
missing differed between experienced and naı¨ve patients but was
still relatively low. As these factors can both independently affect
the risk of virological failure [13,29], these differences may have
affected the strength of the associations with raised viral load
reported in our study. Fourthly, we used a single VL measurement
$1000 copies/mL as a measure of raised viral load. Up to 60% of
patients with VL $1000 copies/mL may be able to suppress VL
with further measures to address adherence [15,37], but due to
only a single measurement we were unable to assess the potential
effect on subsequent viral load levels of enhanced adherence
counselling after an initial high viral load. Finally, the absence of
genotypic resistance testing precluded the assessment of virological
outcomes by baseline ARV resistance in experienced patients.
However this is the current reality in by far the majority of
resource-limited settings and the demonstrated factors associated
with virological outcomes in our study remain useful.
Conclusions
Patients who had been exposed to ARVs for any period and of
any type before coming to MSF for free comprehensive HIV care
had increased OR of raised viral load. The cost and availability of
ARVs were common reasons for missing ARVs before joining the
MSF/MoH clinic, and inadequate patient knowledge was
associated with raised viral load. Other factors associated with
raised viral load were self-reported adherence, ever completely or
partially interrupting current (MSF/MoH) ART, and low CD4
count at the time of VL measurement.
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